Bisphosphonates and osteonecrosis of the jaw

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1049-1051

  Shenker, N G ^a   Jawad, A S M ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHLORHEXIDINE; CLINDAMYCIN; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; GLUCOCORTICOID; HYDROGEN PEROXIDE; IBANDRONIC ACID; PAMIDRONIC ACID; PENICILLIN G; RISEDRONIC ACID; STEROID; THALIDOMIDE; TILUDRONIC ACID; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; ALCOHOL ABUSE; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; AVASCULAR NECROSIS; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CLINICAL FEATURE; COMPLEX REGIONAL PAIN SYNDROME; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOTOXICITY; DENTAL SURGERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; EYE INFLAMMATION; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; IRRADIATION; JAW DISEASE; KIDNEY FAILURE; MOUTH HYGIENE; MULTIPLE MYELOMA; MYALGIA; NEPHROTIC SYNDROME; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; WOUND HEALING IMPAIRMENT;

BONE REMODELING; DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; OSTEOPOROSIS;

EID: 34447299124     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem106     Document Type: Editorial

References (15)

1. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-52.
2. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
3. Woo SB, Hellstein JW, Kalmar J. Systematic review: Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006;144:753-61.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
5. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: The rheumatologist's role. Arth Res Ther 2006;8:219.
6. Kavanagh KL, Guo K, Dunford JE et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci 2006;13:7829-34.
7. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Br Med J 2003;327:469-72.
8. Silverman SL, Maricic M. Recent developments in bisphosphonates therapy. Semin Arthritis Rheum 2007;36:341-45.
9. American Dental Association Council on Scientific Affairs. Expert panel reoommendations: Dental management of patients receiving oral bisphosphonate therapy. J Am Dental Assoc 2006;137:1144-50.
10. Marx RE. Pamidronate (Aredia) and zoledronic acid (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-17.
11. Grey A, Cundy T. Letter: Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006;145:791.
12. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? New Engl J Med 2006;355:2278-81.
13. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
14. Mashiba T, Mori S, Burr DB et al. The effects of suppressed bone remodelling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23(Suppl):36-42.
15. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA 2006;296:2927-38.